Transplant-associated hyperglycemia

Transplantation Reviews

Volumn 22, Issue 1, 2008, Pages 39-51

  Bloom, Roy D ^a   Crutchlow, Michael F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; MEGLITINIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATEGLINIDE; PIOGLITAZONE; PREDNISOLONE; PREDNISONE; RAPAMYCIN; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; TACROLIMUS; TROGLITAZONE; UNINDEXED DRUG;

ARTICLE; ATHEROGENESIS; BLOOD GLUCOSE MONITORING; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DIABETOGENESIS; DIET THERAPY; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLUCONEOGENESIS; GLYCEMIC CONTROL; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INFECTION; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; NEW ONSET DIABETES MELLITUS AFTER TRANSPLANTATION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PREVALENCE; QUALITY OF LIFE; RISK FACTOR; SIDE EFFECT; SURGICAL MORTALITY; SURVIVAL RATE; WEIGHT GAIN;

ATHEROSCLEROSIS; HEART TRANSPLANTATION; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X; ORGAN TRANSPLANTATION; QUALITY OF LIFE;

EID: 36349027520     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2007.06.001     Document Type: Article

References (156)

1. Callaghan C.J., and Bradley J.A. Current status of renal transplantation. Methods Mol Biol 333 (2006) 1-28
2. John P.R., and Thuluvath P.J. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 8 (2002) 708-713
3. Kasiske B.L., Snyder J.J., Gilbertson D., and Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3 (2003) 178-185
4. Kasiske B.L. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 72 (2001) S5-S8
5. Baid S., Cosimi A.B., Farrell M.L., et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 72 (2001) 1066-1072
6. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 (2006) 869-879
7. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting, Barcelona, Spain, 19 February 2003. Transplantation 75 (2003) SS3-SS24
8. American Diabetes Association. Position statement. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
9. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354 (1999) 617-621
10. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
11. Saydah S.H., Loria C.M., Eberhardt M.S., and Brancati F.L. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24 (2001) 447-453
12. Cosio F.G., Kudva Y., van der Velde M., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67 (2005) 2415-2421
13. Bjornholt J.V., Erikssen G., Aaser E., et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 22 (1999) 45-49
14. The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161 (2001) 397-405
15. Navasa M., Bustamante J., Marroni C., et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 25 (1996) 64-71
16. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3 (2003) 590-598
17. Heisel O., Heisel R., Balshaw R., and Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4 (2004) 583-595
18. Montori V.M., Basu A., Erwin P.J., Velosa J.A., Gabriel S.E., and Kudva Y.C. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 25 (2002) 583-592
19. Hebert P.L., Geiss L.S., Tierney E.F., Engelgau M.M., Yawn B.P., and McBean A.M. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14 (1999) 270-277
20. Nam J.H., Mun J.I., Kim S.I., et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 71 (2001) 1417-1423
21. Pascual M., Theruvath T., Kawai T., Tolkoff-Rubin N., and Cosimi A.B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346 (2002) 580-590
22. Khalili M., Lim J.W., Bass N., Ascher N.L., Roberts J.P., and Terrault N.A. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 10 (2004) 349-355
23. Cavaille-Coll M.W., and Elashoff M.R. Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 65 (1998) 142-145
24. Hertz M.I., Taylor D.O., Trulock E.P., et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant 21 (2002) 950-970
25. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
26. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
27. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
28. Ducloux D., Kazory A., Simula-Faivre D., and Chalopin J.M. One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 5 (2005) 2922-2928
29. Armstrong K.A., Campbell S.B., Hawley C.M., Nicol D.L., Johnson D.W., and Isbel N.M. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 5 (2005) 2710-2718
30. Chen J., Muntner P., Hamm L.L., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140 (2004) 167-174
31. Humphrey L.L., Ballard D.J., Frohnert P.P., Chu C.P., O'Fallon W.M., and Palumbo P.J. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med 111 (1989) 788-796
32. Palaniappan L., Carnethon M., and Fortmann S.P. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 16 (2003) 952-958
33. Whelton P.K., Perneger T.V., He J., and Klag M.J. The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J Hum Hypertens 10 (1996) 683-689
34. de Vries A.P., Bakker S.J., van Son W.J., et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 4 (2004) 1675-1683
35. Porrini E., Delgado P., Bigo C., et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 48 (2006) 134-142
36. Cordero Fort A., Gavira J.J., Alegria-Barrero E., et al. Prevalence of metabolic syndrome in heart transplant patients: role of previous cardiopathy and years since the procedure-the TRACA study. J Heart Lung Transplant 25 (2006) 1192-1198
37. Escobar A., Ventura H.O., Stapleton D.D., et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 74 (1994) 1042-1046
38. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 23 (2004) S187-S193
39. Valantine H., Rickenbacker P., Kemna M., et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 103 (2001) 2144-2152
40. Senechal M., Lemieux I., Beucler I., et al. Features of the metabolic syndrome of "hypertriglyceridemic waist" and transplant coronary artery disease. J Heart Lung Transplant 24 (2005) 819-826
41. Kobashigawa J.A., Starling R.C., Mehra M.R., et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transplant 25 (2006) 1063-1069
42. Marchesini G., Marzocchi R., Agostini F., and Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16 (2005) 421-427
43. Sanyal A.J., Contos M.J., Sterling R.K., et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98 (2003) 2064-2071
44. Mindikoglu A.L., Regev A., Casanova-Romero P.Y., et al. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation. Transplant Proc 38 (2006) 1440-1444
45. Cohen D.J., St Martin L., Christensen L.L., Bloom R.D., and Sung R.S. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 6 (2006) 1153-1169
46. Dawwas M.F., Gimson A.E., Lewsey J.D., Copley L.P., and van der Meulen J.H. Survival after liver transplantation in the United Kingdom and Ireland compared with the United States. Gut (2007)
47. Revanur V.K., Jardine A.G., Kingsmore D.B., Jaques B.C., Hamilton D.H., and Jindal R.M. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 15 (2001) 89-94
48. Cosio F.G., Pesavento T.E., Kim S., Osei K., Henry M., and Ferguson R.M. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62 (2002) 1440-1446
49. Taylor D.O., Edwards L.B., Mohacsi P.J., et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J Heart Lung Transplant 22 (2003) 616-624
50. Lentine K.L., Brennan D.C., and Schnitzler M.A. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 16 (2005) 496-506
51. Ducloux D., Kazory A., and Chalopin J.M. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 79 (2005) 438-443
52. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
53. Khaw K.T., Wareham N., Bingham S., Luben R., Welch A., and Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141 (2004) 413-420
54. Selvin E., Coresh J., Golden S.H., Brancati F.L., Folsom A.R., and Steffes M.W. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165 (2005) 1910-1916
55. John P.R., and Thuluvath P.J. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 34 (2001) 889-895
56. Foxton M.R., Quaglia A., Muiesan P., et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 6 (2006) 1922-1929
57. Lecube A., Hernandez C., Genesca J., and Simo R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care 29 (2006) 1140-1149
58. Lang C.C., Beniaminovitz A., Edwards N., and Mancini D.M. Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant 22 (2003) 244-249
59. Porte Jr. D. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev 17 (2001) 181-188
60. Bloom R.D., and Lake J.R. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 6 (2006) 2232-2237
61. Wilkinson A., Davidson J., Dotta F., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 19 (2005) 291-298
62. Eaton R.P., Allen R.C., and Schade D.S. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab 56 (1983) 1294-1300
63. Kruszynska Y.T., Home P.D., and McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology 14 (1991) 103-111
64. Rubenstein A.H., Mako M.E., and Horwitz D.L. Insulin and the kidney. Nephron 15 (1975) 306-326
65. Rabkin R., Ryan M.P., and Duckworth W.C. The renal metabolism of insulin. Diabetologia 27 (1984) 351-357
66. Snyder R.W., and Berns J.S. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 17 (2004) 365-370
67. Williams J.J., Lund L.H., LaManca J., et al. Excessive weight gain in cardiac transplant recipients. J Heart Lung Transplant 25 (2006) 36-41
68. Johnson C.P., Gallagher-Lepak S., Zhu Y.R., et al. Factors influencing weight gain after renal transplantation. Transplantation 56 (1993) 822-827
69. Pfeiffer T., Albrecht K.H., Wagner K., Herget S., and Eigler F.W. The effect of obesity on outcome of kidney transplantation. Med Klin (Munich) 89 (1994) 635-639
70. Richards J., Gunson B., Johnson J., and Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 18 (2005) 461-466
71. Thoma B., Grover V.K., and Shoker A. Prevalence of weight gain in patients with better renal transplant function. Clin Nephrol 65 (2006) 408-414
72. Dengel D.R., Kelly A.S., Olson T.P., Kaiser D.R., Dengel J.L., and Bank A.J. Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. Metabolism 55 (2006) 907-911
73. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
74. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
75. Pirsch J.D., Miller J., Deierhoi M.H., Vincenti F., and Filo R.S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63 (1997) 977-983
76. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344 (1994) 423-428
77. Grimm M., Rinaldi M., Yonan N.A., et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 6 (2006) 1387-1397
78. Duijnhoven E.M., Boots J.M., Christiaans M.H., Wolffenbuttel B.H., and Van Hooff J.P. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 12 (2001) 583-588
79. Boots J.M., van Duijnhoven E.M., Christiaans M.H., Wolffenbuttel B.H., and van Hooff J.P. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 13 (2002) 221-227
80. Filler G., Neuschulz I., Vollmer I., Amendt P., and Hocher B. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 15 (2000) 867-871
81. Heit J.J., Apelqvist A.A., Gu X., et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 443 (2006) 345-349
82. Herold K.C., Nagamatsu S., Buse J.B., Kulsakdinun P., and Steiner D.F. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation 55 (1993) 186-192
83. Hahn H.J., Dunger A., Laube F., et al. Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia 29 (1986) 489-494
84. Redmon J.B., Olson L.K., Armstrong M.B., Greene M.J., and Robertson R.P. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 98 (1996) 2786-2793
85. Olefsky J.M., Johnson J., Liu F., Jen P., and Reaven G.M. The effects of acute and chronic dexamethasone administration on insulin binding to isolated rat hepatocytes and adipocytes. Metabolism 24 (1975) 517-527
86. Olefsky J.M. Effect of dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest 56 (1975) 1499-1508
87. Magnuson M.A., Quinn P.G., and Granner D.K. Multihormonal regulation of phosphoenolpyruvate carboxykinase-chloramphenicol acetyltransferase fusion genes. Insulin's effects oppose those of cAMP and dexamethasone. J Biol Chem 262 (1987) 14917-14920
88. Arner P., Gunnarsson R., Blomdahl S., and Groth C.G. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 6 (1983) 23-25
89. David D.S., Cheigh J.S., Braun Jr. D.W., Fotino M., Stenzel K.H., and Rubin A.L. HLA-A28 and steroid-induced diabetes in renal transplant patients. JAMA 243 (1980) 532-533
90. Friedman E.A., Shyh T.P., Beyer M.M., Manis T., and Butt K.M. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 5 (1985) 196-202
91. Borrows R., Chan K., Loucaidou M., et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation 81 (2006) 125-128
92. Haririan A., Sillix D.H., Morawski K., et al. Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant 6 (2006) 2396-2402
93. Heilman R.L., Mazur M.J., Reddy K.S., Moss A., Post D., and Mulligan D. Steroid avoidance immunosuppression in low-risk kidney transplant recipients. Transplant Proc 37 (2005) 1785-1788
94. Sivaraman P., Nussbaumer G., and Landsberg D. Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am J Kidney Dis 37 (2001) 1162-1169
95. Midtvedt K., Hjelmesaeth J., Hartmann A., et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 15 (2004) 3233-3239
96. Rike A., Mogilishetty G., Alloway R., et al. Metabolic Syndrome in Renal Transplantation: Comparison of Early Corticosteroid Withdrawal Versus Chronic Corticosteroid Therapy. Abstract: 2006 World Transplant Congress (2006)
97. Kreis H., Cisterne J.M., Land W., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69 (2000) 1252-1260
98. Johnson R.W., Kreis H., Oberbauer R., Brattstrom C., Claesson K., and Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777-786
99. Romagnoli J., Citterio F., Nanni G., et al. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 38 (2006) 1034-1036
100. Teutonico A., Schena P.F., and Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16 (2005) 3128-3135
101. Syed N.A., and Khandelwal R.L. Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 211 (2000) 123-136
102. Mittelman S.D., and Bergman R.N. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 279 (2000) E630-E637
103. Lewis G.F., Carpentier A., Adeli K., and Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23 (2002) 201-229
104. Kwon G., Marshall C.A., Liu H., Pappan K.L., Remedi M.S., and McDaniel M.L. Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. J Biol Chem 281 (2006) 3261-3267
105. Kwon G., Marshall C.A., Pappan K.L., Remedi M.S., and McDaniel M.L. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 53 Suppl 3 (2004) S225-S232
106. Bussiere C.T., Lakey J.R., Shapiro A.M., and Korbutt G.S. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 49 (2006) 2341-2349
107. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
108. Gray H., Wreghitt T., Stratton I.M., Alexander G.J., Turner R.C., and O'Rahilly S. High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 12 (1995) 244-249
109. Mehta S.H., Brancati F.L., Sulkowski M.S., Strathdee S.A., Szklo M., and Thomas D.L. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133 (2000) 592-599
110. Ozyilkan E., Erbas T., Simsek H., Telatar F., Kayhan B., and Telatar H. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med 235 (1994) 283-284
111. Simo R., Hernandez C., Genesca J., Jardi R., and Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19 (1996) 998-1000
112. Abbott K.C., Lentine K.L., Bucci J.R., et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 15 (2004) 3166-3174
113. Bloom R.D., Rao V., Weng F., Grossman R.A., Cohen D., and Mange K.C. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13 (2002) 1374-1380
114. Aytug S., Reich D., Sapiro L.E., Bernstein D., and Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 38 (2003) 1384-1392
115. Delgado-Borrego A., Casson D., Schoenfeld D., et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 77 (2004) 703-710
116. Kawaguchi T., Yoshida T., Harada M., et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165 (2004) 1499-1508
117. Masini M., Campani D., Boggi U., et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care 28 (2005) 940-941
118. Konrad T., Zeuzem S., Vicini P., et al. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 30 (2000) 111-121
119. Kamar N., Toupance O., Buchler M., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14 (2003) 2092-2098
120. Gursoy M., Koksal R., Karavelioglu D., et al. Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients. Transplant Proc 32 (2000) 580-582
121. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
122. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
123. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
124. Kasiske B.L., Chakkera H.A., and Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11 (2000) 1735-1743
125. Crutchlow M.F., and Bloom R.D. Transplant-associated hyperglycemia: a new look at an old problem. Clin J Am Soc Nephrol 2 (2007) 343-355
126. Van den Berghe G., Wilmer A., Milants I., et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 55 (2006) 3151-3159
127. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (2001) 1359-1367
128. Armstrong K.A., Prins J.B., Beller E.M., et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients. Clin J Am Soc Nephrol 1 (2006) 100-108
129. Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl 11 (2005) 612-620
130. Miller J., Mendez R., Pirsch J.D., and Jensik S.C. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 69 (2000) 875-880
131. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69 (2000) 834-841
132. Hirsch I.B. Insulin analogues. N Engl J Med 352 (2005) 174-183
133. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
134. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
135. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
136. Watanabe I., Tani S., Anazawa T., Kushiro T., and Kanmatsuse K. Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. Diabetes Res Clin Pract 68 (2005) 104-110
137. Qayyum R., and Schulman P. Cardiovascular effects of the thiazolidinediones. Diabetes Metab Res Rev 22 (2006) 88-97
138. Graham D.J., Drinkard C.R., and Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 98 (2003) 175-179
139. Kaplan B., Friedman G., Jacobs M., et al. Potential interaction of troglitazone and cyclosporine. Transplantation 65 (1998) 1399-1400
140. Villanueva G., and Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 80 (2005) 1402-1405
141. Luther P., and Baldwin Jr. D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 4 (2004) 2135-2138
142. Baldwin Jr. D., and Duffin K.E. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 77 (2004) 1009-1014
143. Pietruck F., Kribben A., Van T.N., et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 18 (2005) 483-486
144. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiac outcomes; an interim analysis. N Engl J Med 357 (2007) Epub ahead of print: July 5, 2007 doi:10.1056/NEJMoa073394
145. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
146. Kosuge H., Haraguchi G., Koga N., Maejima Y., Suzuki J., and Isobe M. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 113 (2006) 2613-2622
147. Turk T., Pietruck F., Dolff S., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 6 (2006) 842-846
148. Kendall D.M., Kim D., and Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 8 (2006) 385-396
149. Miller S., and St Onge E.L. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 40 (2006) 1336-1343
150. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544
151. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
152. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
153. Prasad G.V., Kim S.J., Huang M., et al. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins). Am J Transplant 4 (2004) 1897-1903
154. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4 Suppl 7 (2004) 13-53
155. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30 (2004) 498-505
156. Bosch J., Yusuf S., Gerstein H.C., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562